Free Trial
NASDAQ:RAPP

Rapport Therapeutics (RAPP) Stock Price, News & Analysis

Rapport Therapeutics logo
$14.58 -0.80 (-5.17%)
As of 02:29 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Rapport Therapeutics Stock (NASDAQ:RAPP)

Key Stats

Today's Range
$14.24
$15.70
50-Day Range
$8.40
$15.38
52-Week Range
$6.43
$29.74
Volume
59,979 shs
Average Volume
165,343 shs
Market Capitalization
$532.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.00
Consensus Rating
Buy

Company Overview

Rapport Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
39th Percentile Overall Score

RAPP MarketRank™: 

Rapport Therapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 680th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Rapport Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Rapport Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Rapport Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Rapport Therapeutics are expected to grow in the coming year, from ($3.65) to ($3.37) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Rapport Therapeutics is -4.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Rapport Therapeutics is -4.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Rapport Therapeutics has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Rapport Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    16.26% of the float of Rapport Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Rapport Therapeutics has a short interest ratio ("days to cover") of 16, which indicates bearish sentiment.
  • Change versus previous month

  • Dividend Yield

    Rapport Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Rapport Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    16.26% of the float of Rapport Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Rapport Therapeutics has a short interest ratio ("days to cover") of 16, which indicates bearish sentiment.
  • Change versus previous month

  • News Sentiment

    Rapport Therapeutics has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Rapport Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for RAPP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Rapport Therapeutics to their MarketBeat watchlist in the last 30 days.
Receive RAPP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rapport Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RAPP Stock News Headlines

Breakthroughs Backed by Wall Street - This image is an original composition by MarketBeat using licensed and editorial elements. Not for redistribution or reuse.
Analysts Can't Get Enough of These Little-Known Biopharma Stocks (RAPP)
Three relatively unknown biopharma firms receive near-unanimous approval from analysts for their promising drug candidates in development.
"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
See More Headlines

RAPP Stock Analysis - Frequently Asked Questions

Rapport Therapeutics' stock was trading at $17.74 at the start of the year. Since then, RAPP stock has decreased by 18.4% and is now trading at $14.48.

Rapport Therapeutics, Inc. (NASDAQ:RAPP) posted its earnings results on Thursday, May, 8th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.09.

Rapport Therapeutics (RAPP) raised $136 million in an initial public offering (IPO) on Friday, June 7th 2024. The company issued 8,000,000 shares at a price of $17.00 per share.

Shares of RAPP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Rapport Therapeutics investors own include Alpha Metallurgical Resources (AMR), Arch Biopartners (ARCH), Global X Copper Miners ETF (COPX), Hims & Hers Health (HIMS), Karuna Therapeutics (KRTX), Longboard Pharmaceuticals (LBPH) and Navios Maritime Partners (NMM).

Company Calendar

Last Earnings
5/08/2025
Today
7/11/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RAPP
Previous Symbol
NASDAQ:RAPP
CIK
2012593
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

High Price Target
$28.00
Low Price Target
$28.00
Potential Upside/Downside
+82.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.45)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$78.31 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-25.48%
Return on Assets
-24.63%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
31.01
Quick Ratio
31.01

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$8.35 per share
Price / Book
1.84

Miscellaneous

Outstanding Shares
36,500,000
Free Float
N/A
Market Cap
$561.37 million
Optionable
N/A
Beta
N/A
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:RAPP) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners